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OBJECTIVES Changes in coronary plaque color and morphology by statin therapy were evaluated using
coronary angioscopy.
BACKGROUND Coronary plaque stabilization by statin therapy has not been clarified in humans.
METHODS Thirty-one patients with coronary artery disease were divided into either the comparison
group (n 16) or the atorvastatin group (n 15). Before treatment and 12 months after, the
color and complexity of 145 coronary plaques were determined according to angioscopic
findings. The yellow score of the plaque was defined as 0 (white), 1 (light yellow), 2 (yellow),
or 3 (dark yellow), and its disrupted score was defined as 0 (smooth surface) or 1 (irregular
surface) and as 0 (without thrombus) or 1 (with thrombus). In each patient, the mean yellow
score and mean disrupted score were calculated.
RESULTS Mean low-density lipoprotein cholesterol (LDL-C) decreased by 45% in the atorvastatin
group, whereas an increase of 9% was seen in the comparison group. The mean yellow score
decreased from 2.03 to 1.13 in the atorvastatin group, whereas it increased from 1.67 to 1.99
in the comparison group. There was a good correlation between the change in the mean
yellow score and the change in LDL-C levels (r 0.81, p 0.0001). The change in the mean
yellow score and mean disrupted score differed significantly between the two groups (p 
0.002 and p  0.03, respectively).
CONCLUSIONS This is the first report clarifying detailed changes in coronary plaque by statin in humans. This
study indicated that lipid-lowering therapy changes plaque color and morphology and should
then lead to coronary plaque stabilization. (J Am Coll Cardiol 2003;42:680–6) © 2003 by
the American College of Cardiology Foundation
Coronary plaque disruption or erosion with subsequent
thrombus formation is the pathogenesis of acute coronary
syndrome (ACS) (1–6). Primary and secondary prevention
studies with statins have demonstrated the effect of lipid-
lowering therapy on the reduction of ischemic cardiac
See page 687
events. However, the effects of statins on the regression of
atherosclerosis by coronary angiogram were not always
dramatic (7–11). These phenomena have been explained by
the fact that treatment with statins may change the com-
position of coronary plaque and thus lead to plaque stabi-
lization.
Coronary angioscopy provides full color, high-resolution,
three-dimensional images, and this modality enables us to
obtain detailed information on coronary lumens, including
plaque and thrombus. Previous angioscopic studies have
shown that disrupted yellow plaques accompanied with
thrombus formation are frequently noted as culprit lesions
in patients with ACS, whereas smooth white plaques
without thrombus formation are often noted in patients
with stable angina or old myocardial infarction (MI)
(1,2,12). Therefore, the color and morphology of coronary
plaque are regarded as determining factors for plaque
stability or instability.
This angioscopic study was designed to document the
serial changes in plaque color and morphology by lipid-
lowering therapy.
METHODS
Study design. This study was a prospective, open-label,
single-center study of patients with coronary artery disease.
A comparison group was designed in this study for com-
parison with the atorvastatin group. Nevertheless, this study
was non-randomized. Patients were divided into the two
groups according to their serum total cholesterol (T-CHO)
levels at baseline. In those cases where T-CHO at baseline
was under 220 mg/dl, no lipid-lowering medication was
administered, whereas those cases with more than 220
mg/dl received atorvastatin based on the guidelines of the
Japan Atherosclerosis Society. In the atorvastatin group, the
target low-density lipoprotein cholesterol (LDL-C) level
was 100 mg/dl. All patients received dietary counseling.
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Fifteen patients were treated with atorvastatin, and 16
patients did not receive any lipid-lowering medication
(comparison subjects). Before treatment and at the 12-
month follow-up, coronary angiography and angioscopy
were performed. Informed consent was obtained from all
the study patients, and the research protocol was approved
by our institutional review boards. Clinical follow-up visits
occurred every month for up to 12 months. A blood sample
was taken after 1, 2, 3, 6, and 12 months, and data were
collected on compliance and clinical events.
Patients. The subjects in this study were regular patients
who had successfully undergone percutaneous coronary
intervention (PCI) for ischemic heart disease from Decem-
ber 2000 to May 2001.
Exclusion criteria were left main disease, severe three-
vessel disease, MI within the previous four weeks, an
ejection fraction  40%, past administration of any lipid-
lowering medication, secondary causes of hypercholesterol-
emia, severe hypertriglyceridemia (400 mg/dl), and
chronic inflammatory disease. Patients who had no angio-
scopic yellow or disrupted plaques, except those at the PCI
sites, were excluded. Those plaques located within 10 mm
proximal and distal to the percutaneous intervention sites
were also excluded.
Blood and physical examinations. At baseline, systolic
and diastolic blood pressure, fasting plasma glucose, hemo-
globin A1c, serum uric acid, and body mass index were
measured. At baseline and follow-up, fasting serum
T-CHO, triglycerides (TG), high-density lipoprotein cho-
lesterol (HDL-C), and C-reactive protein (CRP) were
measured; LDL-C was calculated according to Friedwald’s
formula.
Medical therapies. The patients in the comparison group
continued with therapies for coronary risk factor reduction
exclusive of hyperlipidemia. The patients in the atorvastatin
group had the administration of atorvastatin added to these
therapies. The initial daily dose of atorvastatin was 10 mg,
and this dose was increased up to 30 mg to reach the target
LDL-C levels (100 mg/dl).
Coronary angiography and target lesion revascularization.
A coronary angiogram was obtained at baseline, six months,
and 12 months follow-up. In the case of angiographic
restenosis at six months, target lesion revascularization was
performed. The vessel contour, such as irregularity and
haziness, in the segments evaluated using coronary angios-
copy was identified by consensus of two independent
angiographers.
Coronary angioscopic imaging. Coronary angioscopic ex-
aminations were performed at baseline and 12 months
follow-up. An imaging catheter (Vecmova, Clinical Supply
Co., Gifu, Japan) was used, and the angioscopic procedure
had been previously reported (1,2,12). Before observation,
the white balance was adjusted for color correction. During
angioscopic observation, an exclusive assistant adjusted the
light power to keep a regular degree of brightness on the
target plaque. Light power was adjusted to avoid reflection
and to obtain images with adequate brightness for deter-
mining plaque color. Angioscopic images and fluoroscopy
during angioscopic observation were recorded on DVD
videotape for analysis later. The exact position of the
angioscopic catheter at the site of target plaque was recorded
by angiogram to ensure a reliable comparison.
Definition and analysis of angioscopic findings. Coro-
nary arteries were observed by coronary angioscopy, and the
existence and number of the yellow or disrupted plaques
were evaluated. For each plaque, the score of the color and
complexity of the coronary plaques were determined as
follows: the yellow score was defined as 0 (white), 1 (light
yellow), 2 (yellow), or 3 (dark yellow), and the disrupted
score was defined as 0 (smooth surface) or 1 (irregular
surface) and as 0 (without thrombus) or 1 (with thrombus)
(Fig. 1). In each patient, the mean yellow score and mean
disrupted score were calculated as the total of the yellow
score and disrupted score of all the plaques divided by the
number of plaques, respectively.
Angioscopic images were analyzed independently by two
observers blinded to treatment assignment, patients’ clinical
background, and the order of the angioscopic examination.
The intra-observers agreement was measured by having an
observer repeat the assessment of 20 images (presented in
random order) one week later. The inter-observer agree-
ment was measured by having the two observers compare
the assessment of the 20 images. Intra- and inter-observer
agreements were both 95%. If there was no consensus
concerning the angioscopic scores, the data in question were
excluded from the study.
Statistical analysis. Data are presented as the mean SD.
Whether data were normally distributed or not was exam-
ined by the Kolmogrov-Smirnov test. If data were normally
distributed, an unpaired Student t test was used to compare
the two groups. Otherwise, a Mann Whitney U test was
used. The changes in lipoprotein levels, CRP levels, and
angioscopic scores in each group from baseline to follow-up
were tested with a paired Student t test. Differences in the
changes in angioscopic scores from baseline to follow-up
between the two groups were analyzed with analysis of
covariance, in which changes in angioscopic scores are the
dependent variables and in which treatment with atorvasta-
tin and angioscopic scores at baseline are the independent
variables. The categorical variable was analyzed using the
Abbreviations and Acronyms
ACS  acute coronary syndrome
CRP  C-reactive protein
HDL-C  high-density lipoprotein cholesterol
IMT  intima-media thickness
LDL-C  low-density lipoprotein cholesterol
MI  myocardial infarction
PCI  percutaneous coronary intervention
T-CHO  total cholesterol
TG  triglycerides
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Fisher exact probability test. The correlation between the
two parameters was evaluated by linear regression analysis.
A p value of 0.05 was considered statistically significant.
RESULTS
Baseline characteristics of the patients. Thirty-three pa-
tients were screened to find yellow or disrupted plaques
using coronary angioscopy. Two patients were excluded
because they had no yellow or disrupted plaques except
those at the PCI sites. Finally, 31 patients were examined in
this study.
Clinical characteristics at baseline except for lipoprotein
levels were comparable in the comparison group (n  16)
and the atorvastatin group (n  15) (Table 1).
Changes in lipoprotein levels and CRP levels. Changes
in lipoprotein levels and CRP levels in the two groups are
shown (Table 2). At baseline, T-CHO and LDL-C levels
were significantly higher in the atorvastatin group than in
the comparison group. In the comparison group, T-CHO
and LDL-C increased during follow-up, whereas, in the
atorvastatin group, T-CHO, TG, and LDL-C decreased
significantly by 35%, 31%, and 45%, respectively. Target
LDL-C levels were obtained by one patient in the compar-
ison group and by 10 patients in the atorvastatin group. The
final daily dose of atorvastatin was 10 mg in eight, 20 mg in
six, and 30 mg in one patient, respectively.
C-reactive protein levels did not change in the two
groups. There was a tendency for CRP levels in the
atorvastatin group to decrease.
Coronary angiography. At baseline, three segments in the
comparison group and three segments in the atorvastatin
group were identified as angiographic irregularities. The
segment accompanied with haziness was not recognized. At
the 12-month follow-up, irregularity remained in three
segments in the comparison group while it disappeared in
two segments in the atorvastatin group. There was no new
Figure 1. (A) White plaque (yellow score: 0). (B) Light yellow plaque
(yellow score: 1). (C) Yellow plaque (yellow score: 2). (D) Dark yellow
plaque (yellow score: 3). (E) Yellow and irregular plaque (disrupted score:
1). (F) Yellow plaque with a red thrombus (disrupted score: 1).
Table 1. Baseline Characteristics of Patients in the Comparison
and Atorvastatin Groups
Comparison
(n  16)
Atorvastatin
(n  15) p Value
Age (yrs) 62  9 59  10 0.39
Gender (male) 14 (88) 11 (73) 0.29
Risk factors for coronary artery
disease
Hypertension 12 (75) 7 (47) 0.11
Diabetes mellitus 5 (31) 3 (20) 0.38
Current smoker 8 (50) 10 (67) 0.28
Obesity 4 (25) 6 (40) 0.30
Family history 4 (25) 4 (27) 0.62
Hyperuricemia 2 (13) 2 (13) 0.68
Diagnosis for coronary artery
disease
Myocardial infarction
(convalescent stage)
13 (81) 9 (60) 0.18
Stable angina 2 (13) 4 (27) 0.29
Unstable angina 1 (6) 2 (13) 0.47
Number of diseased vessels
One-vessel disease 10 (63) 9 (60) 0.59
Two-vessel disease 6 (38) 6 (40)
Medication use:
Aspirin 15 (94) 14 (93) 0.74
Ticlopidine 13 (81) 13 (87) 0.53
Warfarin 1 (6) 0 (0) 0.52
Beta-blockers 5 (31) 5 (33) 0.60
Calcium channel blockers 6 (38) 4 (27) 0.40
Angiotensin-converting enzyme
inhibitors
6 (38) 8 (53) 0.30
Angiotensin II receptor
antagonists
6 (38) 2 (13) 0.13
Diuretics 1 (6) 1 (7) 0.75
Oral hypoglycemic agents 2 (13) 3 (20) 0.47
Insulin 1 (6) 0 (0) 0.52
Systolic blood pressure (mm Hg) 123  12 119  11 0.34
Diastolic blood pressure (mm Hg) 74  12 69  7 0.17
Fasting plasma glucose (mg/dl) 105  16 105  24 1.00
Hemoglobin A1c (%) 5.5  1.1 5.5  1.1 1.00
Uric acid (mg/dl) 6.0  1.4 5.4  1.4 0.24
Body mass index (kg/m2) 23.8  1.9 24.4  3.1 0.52
Except for age, systolic and diastolic blood pressure, fasting plasma glucose,
hemoglobin A1c, uric acid, and body mass index, which are the mean  SD, values
represent n (%).
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appearance of angiographic irregularity or haziness in either
group.
Clinical outcome. There were no withdrawals due to
drug-related side effects in either group. Three patients in
the comparison group and two patients in the atorvastatin
group underwent target lesion revascularization based on
angiographic restenosis at six months. There was no occur-
rence of ACS in either group.
Analysis of angioscopic findings. A total of 152 yellow or
disrupted plaques in 63 coronary arteries were identified at
baseline. Seven plaques, whose angioscopic scores at base-
line or follow-up could not be agreed on by the observers,
were excluded. Therefore, 145 coronary plaques were used
for this study (Table 3). The changes in the mean yellow
score and mean disrupted score of the two groups are shown
in Figure 2. At baseline, there were no significant differences
in these scores between the two groups. In the atorvastatin
group, these two angioscopic scores decreased significantly
from baseline to follow-up. In the comparison group, the
mean yellow score increased significantly. The changes in
the mean yellow score and mean disrupted score between
the two groups differed significantly (p  0.002 and p 
0.03, respectively). In the atorvastatin group, three thrombi
disappeared, and five irregular plaques changed into smooth
plaques. In the comparison group, two thrombi appeared,
one thrombus disappeared, and five smooth plaques
changed into irregular plaques. Two typical cases are shown
in Figure 3. There was a good correlation between the
change in the mean yellow score and the change in LDL-C
levels (Fig. 4). There was no correlation between the change
in the mean disrupted score and the change in LDL-C
levels (r  0.42, p  0.10).
DISCUSSION
Histological studies have revealed that atherosclerotic
plaques prone to disruption, so-called “vulnerable plaques,”
are commonly composed of a thin fibrous cap, lipid-rich
cores, and many inflammatory cells, such as macrophages,
foam cells, and T-lymphocytes (3,4). Previous angioscopic
studies have established that irregular yellow plaques with
thrombus are commonly observed at the sites of culprit
lesions in patients with ACS (1,2). Furthermore, a prospec-Ta
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Table 3. Number and Distribution of Coronary Plaques
Comparison
Group
Atorvastatin
Group p Value
Number of coronary plaques 68 77
Number of observed coronary
arteries by coronary angioscopy
Right coronary artery 10 7 0.37
Left anterior descending artery 7 10 0.21
Left circumflex artery 16 13 0.44
Distribution of coronary plaques
Right coronary artery 26 22 0.15
Left anterior descending artery 24 26 0.49
Left circumflex artery 18 29 0.10
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tive study has demonstrated that yellow plaque frequently
causes ACS (13). In contrast, smooth white plaque, often
observed in ischemia-related lesions of patients with stable
angina or old MI, has a thick fibrous cap or is completely
fibrous (12,14,15). These facts suggest that the color and
complexity are the determinant factors of plaque stability or
instability. In general, yellow plaque is believed to be more
vulnerable than white plaque (12,16,17). However, the
grade of the yellow plaque varies. In this study, the color and
complexity of the coronary plaques were evaluated semi-
quantitatively as angioscopic scores. We hypothesized that
lipid-lowering therapy would change the quality of the
plaque and that this change would be recognized as a
reduction of the yellow score and disrupted score by coro-
nary angioscopy.
Changes in plaque color. This study indicated that lipid-
lowering therapy by atorvastatin dramatically decreased the
yellow grade of coronary plaque. An experimental study
revealed that lipid-lowering by diet reduced matrix metal-
loproteinase activity and increased collagen content in rabbit
atheroma (18). A pathological study of human carotid
plaques obtained by carotid endoatherectomy demonstrated
that a lipid-lowering therapy with pravastatin decreased
lipid content and inflammatory activity and increased col-
lagen content (19). Similar changes in coronary plaques
might be caused by a lipid-lowering therapy in living
humans. A recent in vivo study of the comparison between
integrated backscatter intravascular ultrasound and coronary
angioscopy revealed that plaque color in angioscopy de-
pended not on the thickness of the lipid-core but on the
thickness of the fibrous cap (15). Increased collagen content
should make thin fibrous caps thicker. Therefore, increased
collagen content and decreased lipid content of coronary
plaques by lipid-lowering therapy appear to reduce angio-
scopic yellow grade.
In the comparison group, the mean yellow score increased
at the 12-month follow-up in spite of baseline T-CHO
levels 220 mg/dl. A previous prospective, randomized,
double-blind trial showed that a conventional lipid-
lowering therapy with simvastatin for two years was associ-
ated with increased intima-media thickness (IMT) of the
carotid artery, whereas an aggressive lipid-lowering therapy
with high doses of atorvastatin decreased the IMT in
patients with familial hypercholesterolemia (20). A three-
dimensional intravascular ultrasound study showed that one
year of conventional therapy for hyperlipidemia, excluding
atorvastatin, increased the volume of the coronary plaques
(21). These facts suggest that atherosclerosis progresses
during conventional therapies for hyperlipidemia. There-
fore, the increase in the mean yellow score in the compar-
ison group may be indicative of the natural progression of
atherosclerosis.
Changes in plaque complexity. In the atorvastatin group,
three thrombi had disappeared at the follow-up. Statins
have not only a direct lipid-lowering action but also other
indirect actions, so-called “pleiotropic effects.” An anti-
thrombic effect is one of these pleiotropic effects. Statins
prevent the expression of endothelial tissue factor (22).
Moreover, atorvastatin reduced TG levels by 31% in this
study. It is well known that the reduction in TG levels
decreases plasminogen activator inhibitor-1 activity, which
is a major inhibitor of the fibrinolytic system. Atorvastatin
also inhibits platelet deposition on eroded vessel walls (23).
These effects of atorvastatin must indicate antithrombic and
platelet inhibition. The disappearance of coronary thrombi
may be explained by the fact that atorvastatin has anti-
thrombic and platelet inhibition effects.
In five plaques, an irregular surface changed into a
smooth surface after treatment with atorvastatin. The pre-
cise mechanism of this morphologic change in the plaques
has been unknown. However, this change may be one of the
processes involved in plaque stabilization.
Changes in CRP levels. A recent pathological study with
coronary arteries demonstrated that there was a positive
correlation between the staining intensity for CRP of
macrophages, lipid-core, and serum CRP levels. Moreover,
a strong correlation between serum CRP levels and in-
Figure 2. Changes in mean yellow score and mean disrupted score from
baseline to follow-up. The open circles represent the comparison group (n
 16); the open squares represent the atorvastatin group (n  15). In the
atorvastatin group, the mean yellow score and mean disrupted score
decreased significantly from baseline to follow-up. In the comparison
group, the mean yellow score increased significantly.
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creased number of coronary atheromas with thin fibrous
caps was revealed (24). These facts suggest that CRP is a
marker for coronary atherosclerosis, especially those lesions
rich in lipid-core and macrophages. In this study, the serum
concentration of CRP in the atorvastatin group tended to
decrease. Atorvastatin inhibits inflammatory cell activity in
atherosclerotic plaques. In a rabbit model of atherosclerosis,
atorvastatin abolished macrophage infiltration and de-
creased monocyte chemoattractant protein levels in the
neointima and in the media (25). The tendency of CRP
reduction in the atorvastatin group may be reflected in
coronary plaque stabilization by an anti-inflammatory effect.
Changes in LDL-C levels and the mean yellow score.
This study revealed that there was a good correlation
between the change in the mean yellow score and the
change in LDL-C levels. Previous biochemical study dem-
onstrated that treatment with atorvastatin decreased not
only native LDL-C but also oxidized LDL-C in patients
with hyperlipidemia (26). Oxidized LDL-C plays a key role
in the process of atherosclerosis. Oxidized LDL-C is taken
in macrophages through the scavenger receptors. These
macrophages transform into foam cells, and then they are
deposited as lipid-core in the atherosclerotic lesions. Matrix
metalloproteinase derived from macrophages breaks down
various matrix proteins in the fibrous cap and weakens it.
Therefore, LDL-C lowering decreases activity of inflam-
matory cells and lipid content and increases collagen content
(18,19). A decrease of the angioscopic yellow score should
indicate the plaque stabilization resulting from these
changes in plaque composition. Our results support the
theory that aggressive LDL-C lowering is beneficial to
coronary plaque stabilization.
Study limitations. First, the number of patients in the
study was small. However, a total of 145 coronary plaques
were evaluated. Second, the evaluation of plaque color was
rather subjective, although this kind of assessment is easy
Figure 3. Changes in angioscopic findings from baseline to follow-up. (A) A right coronary angiogram of a patient in the atorvastatin group. (B) Yellow
plaque in a patient in the atorvastatin group at baseline. Yellow plaque (yellow score: 3) was observed in the mid-portion of the right coronary artery at
baseline (arrow in A). The surface of this plaque was smooth, and a thrombus was not noted (disrupted score: 0). (C) White plaque in a patient in the
atorvastatin group at follow-up. After treatment with atorvastatin, the yellow plaque changed into a completely white plaque. Both the yellow score and
disrupted score were 0. (D) A right coronary angiogram of a patient in the comparison group. (E) Yellow plaque in a patient in the comparison group at
baseline. Yellow plaque (yellow score: 1) was observed in the mid-portion of the right coronary artery at baseline (arrow in D). The surface of this plaque
was smooth, and a thrombus was not noted (disrupted score: 0). (F) Yellow plaque in a patient in the comparison group at follow-up. After 12 months of follow-up
without lipid-lowering medication, the yellow score had increased to 2, and the surface of this plaque had become irregular (disrupted score: 1).
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and practical. Therefore, those plaques without inter-
observer consensus with regard to angioscopic findings were
excluded from this study. Third, whole angioscopic evalu-
ation in three main coronary arteries was performed in
some, but not all, study patients. Finally, this study was
non-randomized. From an ethical point of view, based on
several prevention studies with statins, those cases with
serum T-CHO more than 220 mg/dl at baseline were
treated for hyperlipidemia.
Conclusions. We have demonstrated that LDL-C lower-
ing by atorvastatin resulted in the reduction of angioscopic
yellow grade and complexity of coronary plaques. A lipid-
lowering therapy changed the quality of coronary plaques
and should lead to coronary plaque stability.
Reprint requests and correspondence: Dr. Kyoichi Mizuno,
Department of Internal Medicine, Nippon Medical School,
Chiba-Hokusoh Hospital, 1715 Kamakari, Imba, Chiba, Japan
270-1694. E-mail: mizunok@nms.ac.jp.
REFERENCES
1. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of
coronary-artery thrombi in acute coronary syndromes. N Engl J Med
1992;326:287–91.
2. Mizuno K, Miyamoto A, Satomura K, et al. Angioscopic macromor-
phology in patients with acute coronary disorders. Lancet 1991;337:
809–12.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation
1995;92:657–71.
4. Libby P. Molecular basis of the acute coronary syndrome. Circulation
1995;91:2844–50.
5. Davies MJ. Stability and instability: two faces of coronary atheroscle-
rosis. Circulation 1996;94:2013–20.
6. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary
artery disease and the acute coronary syndromes. N Engl J Med
1992;326:242–50.
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of
cholesterol lowering in 4444 patients with coronary heart disease.
Lancet 1994;344:1383–9.
8. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart
disease with pravastatin in men with hypercholesterolemia. N Engl
J Med 1995;333:1301–7.
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on
coronary events after myocardial infarction in patients with average
cholesterol levels. N Engl J Med 1996;335:1001–9.
10. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID)
Study Group. Prevention of cardiovascular events and death with
pravastatin in patients with coronary heart disease and a broad range of
initial cholesterol levels. N Engl J Med 1998;339:1349–57.
11. MAAS Investigators. Effect of simvastatin on coronary atheroma: the
multicenter anti-atheroma study (MAAS). Lancet 1994;344:633–8.
12. Takano M, Mizuno K, Okamatsu K, et al. Mechanical and structural
characteristics of vulnerable plaques: analysis by coronary angioscopy
and intravascular ultrasound. J Am Coll Cardiol 2001;38:99–104.
13. Uchida Y, Nakamura F, Tomaru T, et al. Prediction of acute coronary
syndromes by percutaneous angioscopy in patients with stable angina.
Am Heart J 1995;130:195–203.
14. Thieme T, Wernecke KD, Meyer R, et al. Angioscopic evaluation of
atherosclerotic plaques: validation by histomorphologic analysis and
association with stable and unstable coronary syndromes. J Am Coll
Cardiol 1996;28:1–6.
15. Kawasaki M, Takatsu H, Noda T, et al. In vivo quantitative tissue
characterization of human coronary arterial plaques by use of inte-
grated backscatter intravascular ultrasound and comparison with an-
gioscopic findings. Circulation 2002;105:2487–92.
16. Belle EV, Lablanche J-M, Bauters C, et al. Coronary angioscopic
findings in the infarct-related vessel within 1 month of acute myocar-
dial infarction. Circulation 1998;97:26–33.
17. Waxman S, Sassower MA, Mittleman MA, et al. Angioscopic
predictors of early adverse outcome after coronary angioplasty in
patients with unstable angina and non-Q-wave myocardial infarction.
Circulation 1996;93:2106–13.
18. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces
matrix metalloproteinase activity and increased collagen content on
rabbit atheroma. Circulation 1998;97:2433–44.
19. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treat-
ment increases collagen content and decreases lipid content, inflam-
mation, metalloproteinases, and cell death in human carotid plaques:
implications for plaque stabilization. Circulation 2001;103:926–33.
20. Smilde TJ, Wissen SV, Wollersheim H, et al. Effect of aggressive
versus conventional lipid lowering on atherosclerosis progression in
familial hypercholesterolemia (ASAP): a prospective, randomised,
double-blind trial. Lancet 2001;357:577–81.
21. Schartl M, Bocksch W, Koschyk DH, et al., for the German
Atorvastatin Intravascular Ultrasound Study Investigators (GAIN).
Use of intravascular ultrasound to compare effects of different strategies
of lipid-lowering therapy on plaque volume and composition in
patients with coronary artery disease. Circulation 2001;104:387–92.
22. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor
expression in human endothelial cells: role of Rho/Rho kinase and Akt
pathways. Circulation 2002;105:1756–9.
23. Alfon J, Royo T, Garcia-Moll X, et al. Platelet deposition on eroded
vessel walls at stenotic shear rate is inhibited by lipid-lowering
treatment with atorvastatin. Arterioscler Thromb Vasc Biol 1999;19:
1812–7.
24. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein
values and atherosclerosis in sudden coronary death: association with
different pathologies. Circulation 2002;105:2019–23.
25. Bustos C, Herna´ndez-Presa MA, Ortego M, et al. HMG-CoA
reductase inhibition by atorvastatin reduces neointimal inflammation
in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057–
64.
26. Zhu Q, McMaster J, Mymin D, et al. Effects of atorvastatin treatment
on the oxidatively modified low density lipoprotein in hyperlipidemic
patients. Mol Cell Biochem 2000;207:9–17.
Figure 4. Relationship between the change in the mean yellow score and
the change in LDL-C levels from baseline to follow-up. There was a good
correlation between the change in the mean yellow score and the change in
LDL-C levels from baseline to follow-up.
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